Long-term outcome of treatment with infliximab in pediatric-onset Crohn's disease: A population-based study

Inflammatory Bowel Diseases

Volumn 17, Issue 10, 2011, Pages 2144-2152

  Crombé, Valérie ^a   Salleron, Julia ^a   Savoye, Guillaume ^b   Dupas, Jean Louis ^c   Vernier Massouille, Gwénola ^a   Lerebours, Eric ^b   Cortot, Antoine ^a   Merle, Véronique ^b   Vasseur, Francis ^a   Turck, Dominique ^a   Gower Rousseau, Corinne ^a   Lémann, Marc ^d   Colombel, Jean Frédéric ^a   Duhamel, Alain ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b ROUEN UNIVERSITY HOSPITAL   (France)

^c AMIENS UNIVERSITY HOSPITAL   (France)

^d SAINT LOUIS HOSPITAL   (France)

Author keywords

Crohn's disease; infliximab; pediatric; treatment

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; INFLIXIMAB; METHOTREXATE;

ADOLESCENT; ANAPHYLACTIC SHOCK; ARTICLE; AUTOIMMUNE DISEASE; BRADYCARDIA; CHILD; COLON SURGERY; CONTROLLED STUDY; CROHN DISEASE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEART FAILURE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MYCOSIS; POPULATION RESEARCH; PRIORITY JOURNAL; PSORIASIS; PURPURA; REMISSION; SCHOOL CHILD; SERUM SICKNESS; SKIN ABSCESS; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; AGE OF ONSET; ANTIBODIES, MONOCLONAL; CHILD; CROHN DISEASE; FEMALE; FOLLOW-UP STUDIES; FRANCE; GASTROINTESTINAL AGENTS; HUMANS; MALE; REMISSION INDUCTION; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 80052775138     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21615     Document Type: Article

References (44)

1. Russel MG,. Changes in the incidence of inflammatory bowel disease: what does it mean? Eur J Intern Med. 2000; 11: 191-196.
2. Loftus EV,. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004; 126: 1504-1517.
3. Armitage EL, Aldhous MC, Anderson N, et al. Incidence of juvenile-onset Crohn's disease in Scotland: association with northern latitude and affluence. Gastroenterology. 2004; 127: 1051-1057.
4. Kim S, Ferry G,. Inflammatory bowel disease in children. Curr Prob Pediatr Adolesc Health Care. 2002; 32: 108-132.
5. Auvin S, Molinié F, Gower-Rousseau C, et al. Incidence, clinical presentation and location at diagnosis of pediatric inflammatory bowel disease: a prospective population-based study in northern France (1988-1999). J Pediatr Gastroenterol Nutr. 2005; 41: 49-55.
6. Chouraki V, Dauchet L, Vernier-Massouille G, et al. The changing patterns of Crohn's disease incidence according to age in northern France: a constant increase in the 0-19 year's age group (1988-2005). Gastroenterology. 2009; 136 (suppl 1): A20.
7. Vasseur F, Gower-Rousseau C, Vernier-Massouille G, et al. Nutritional status and growth in pediatric Crohn's disease: a population-based study. Am J Gastroenterol. 2010; 105: 1893-1900.
8. Vernier-Massouille G, Baldé M, Salleron J, et al. Natural history of pediatric Crohn's disease: a population-based cohort study. Gastroenterology. 2008; 135: 1106-1113.
9. Van Limbergen J, Russell RK, Drummond HE, et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology. 2008; 135: 1114-1132.
10. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's disease cA2 Study Group. N Engl J Med. 1997; 337: 1029-1035.
11. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002; 359: 1541-1549.
12. Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut. 2009; 58: 492-500.
13. Kugathasan S, Werlin SL, Martinez A, et al. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. Am J Gastroenterol. 2000; 95: 3189-3194.
14. Hyams JS, Markowitz J, Wyllie R,. Use of infliximab in the treatment of Crohn's disease in children and adolescents. J Pediatr. 2000; 137: 192-196.
15. Baldassano R, Braegger CP, Escher JC, et al. Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease. Am J Gastroenterol. 2003; 98: 833-838.
16. Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology. 2007; 132: 863-873
17. Markowitz J, Hyams J, Mack D, et al. Corticosteroid therapy in the age of infliximab: acute and 1-year outcomes in newly diagnosed children with Crohn's disease. Clin Gastrol Hepatol. 2006; 4: 1124-1129.
18. Cézard JP, Nouaili N, Talbotec C, et al. A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (Remicade) in severe pediatric Crohn's disease. J Pediatr Gastroenterol Nutr. 2003; 36: 632-636.
19. Hyams JS, Lerer T, Griffiths A, et al. Long-term outcome of maintenance infliximab therapy in children with Crohn's disease. Pediatric Inflammatory Bowel Disease Collaborative Research Group. Inflamm Bowel Dis. 2009; 15: 816-822.
20. Gower-Rousseau C, Salomez JL, Dupas JL, et al. Incidence of inflammatory bowel disease in northern France (1988-1990). Gut. 1994; 35: 1433-1438.
21. Molinié F, Gower-Rousseau C, Yzet T, et al. Opposite evolution in incidence of Crohn disease and ulcerative colitis in northern France (1988-1999). Gut. 2004; 53: 843-848.
22. Cole TJ, Green PJ,. Smoothing reference centile curves: the LMS method and penalized likelihood. Stat Med. 1992; 11: 1305-1319.
23. Freeman JV, Cole TJ, Chinn S, et al. Cross sectional stature and weight reference curves for the UK, 1990. Arch Dis Child. 1995; 73: 17-24.
24. Fidder H, Schnitzler F, Ferrante M, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut. 2009; 58: 501-508.
25. Serrano MS, Schmidt-Sommerfeld E, Kilbaugh TJ, et al. Use of infliximab in pediatric patients with inflammatory bowel disease. Ann Pharmacother. 2001; 35: 823-828.
26. Stephens MC, Shepanski MA, Mamula P, et al. Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric-inflammatory bowel disease center. Am J Gastroenterol. 2003; 98: 104-111.
27. Lionetti P, Bronzini F, Salvestrini C, et al. Response to infliximab is related to disease duration in pediatric Crohn's disease. Aliment Pharmacol Ther. 2003; 18: 425-431.
28. de Ridder L, Escher JC, Bouquet J, et al. Infliximab therapy in 30 patients with refractory pediatric Crohn's disease with and without fistulas in the Netherlands. J Pediatr Gastroenterol Nutr. 2004; 39: 46-52.
29. Schreiber S, Colombel JF, Bloomfield R, et al. Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol. 2010; 105: 1574-1582.
30. Schreiber S, Reinisch R, Colombel J, et al. Early Crohn's disease shows high levels of remission to therapy with adalimumab: sub-analysis of CHARM. Gastroenterology. 2007; 132: A147.
31. D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet. 2008; 371: 660-667.
32. Wynands J, Belbouab R, Candon S, et al. 12-month follow-up after successful infliximab therapy in pediatric Crohn's disease. J Pediatr Gastroenterol Nutr. 2008; 46: 293-298.
33. Beattie RM, Camacho-Hubner C, Wacharasindhu S, et al. Responsiveness of IGF-1 and IGFBP-3 to therapeutic intervention in children and adolescents with Crohn's disease. Clin Endocrinol. 1998; 49: 483-489.
34. Gronbek H, Thogersen T, Frystyk J, et al. Low free and total insulinlike growth factor I (IGF-1) and IGF binding protein-3 levels in chronic inflammatory bowel disease: partial normalization during prednisolone treatment. Am J Gastroenterol. 2002; 97: 673-678.
35. Heuschkel R, Salvestrini C, Beattie M, et al. Guidelines for the management of growth failure in childhood inflammatory bowel disease. Inflamm Bowel Dis. 2008; 14: 839-849.
36. Borelli O, Bascietto C, Viola F, et al. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease. Dig Liver Dis. 2004; 36: 342-347.
37. Walters TD, Gilman AR, Griffiths AM,. Linear growth improves during infliximab therapy in children with chronically active severe Crohn's disease. Inflamm Bowel Dis. 2007; 13: 424-430.
38. Thayu M, Leonard MB, Hyams JS, et al. Improvement in biomarkers of bone formation during infliximab therapy in pediatric Crohn's disease: results of the REACH study. Clin Gastroenterol Hepatol. 2008; 6: 1378-1384.
39. Diamanti A, Basso MS, Gambarara M, et al. Positive impact of blocking tumor necrosis factor α on the nutritional status in pediatric Crohn's disease patients. Int J Colorectal Dis. 2009; 24: 19-25.
40. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010; 362: 1383-1395.
41. Kinney T, Rawlins M, Kozarek R, et al. Immunomodulators and "on demand" therapy with infliximab in Crohn's disease: clinical experience with 400 infusions. Am J Gastroenterol. 2003; 98: 608-612.
42. Regueiro M, Siemanowski B, Kip KE, et al. Infliximab dose intensification in Crohn's disease. Inflamm Bowel Dis. 2007; 13: 1093-1099.
43. Van Assche G, Paintaud G, D'Haens G, et al. Continuation of immunomodulators is not required to maintain adequate infliximab efficacy in patients with Crohn's disease but may improve pharmacokinetics. Gastroenterology. 2006; 130: A142.
44. Rosh JR, Gross T, Mamula P, et al. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale? Inflamm Bowel Dis. 2007; 13: 1024-1030.